CERS
Cerus Corporation
There isn't enough reported data to score CERS yet.
CERS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Weak |
CERS's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
CERS PE Valuation
CERS has no meaningful PE right now: it lost money over the past year.
CERS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CERS's losses to shrink, with revenue growing.
CERS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.03 | +$0.05 |
| Q2 2026 | -$0.03 | +$0.07 |
| Q1 2026 | -$0.05 | +$0.05 |
| Q4 2025 | -$0.08 | +$0.03 |
| Q3 2025 | -$0.08 | +$0.03 |
| Q2 2025 | -$0.10 | +$0.03 |
| Q1 2025 | -$0.10 | +$0.07 |
| Q4 2024 | -$0.11 | +$0.10 |
CERS is still losing money, but far less than before: $0.03 per share over the past year, against $0.52 at its worst in late 2019.
CERS Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.7% | N/A |
| Q2 2026 | -3.2% | N/A |
| Q1 2026 | -0.7% | N/A |
CERS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.4M | +2471% |
| Q2 2026 | -$3.5M | -$611K |
| Q1 2026 | -$3.3M | -$2.3M |
| Q4 2025 | $4.9M | +24% |
| Q3 2025 | $94K | -97% |
| Q2 2025 | -$2.9M | -912% |
| Q1 2025 | -$956K | -211% |
| Q4 2024 | $4M | +$19.1M |
CERS has burned cash in most quarters: $494,000 over the past year, up 194% from the year before.
CERS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +1.1M shares |
| 1 year | +5.1% | +9.8M shares |
| 3 years | +11% | +20.7M shares |
| 5 years | +17% | +29.7M shares |
| Available history | +44% | +61.8M shares |
CERS has 202M diluted shares, up 5.1% from a year ago.
CERS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 711.2x | High |
CERS's net debt is more than 20 years of its operating earnings (EBITDA).
CERS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 8.0 | Oversold |
CERS's weekly RSI is 40 (neutral) and its Stochastic is 8 (oversold).
CERS PE vs Healthcare Sector
CERS has no meaningful PE right now: it lost money over the past year.
CERS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 13% below |
| 20 week MA | $2.55 | 24% below |
| 50 week MA | $2.39 | 19% below |
| 100 week MA | $1.93 | 0.5% above |
| 200 week MA | $2.00 | 3% below |
CERS's trend is mixed: it's above one of its five weekly moving averages, and 3% below its 200-week average.
CERS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.28 | $8.07 | +89% |
| 2021 | $8.07 | $6.95 | -14% |
| 2022 | $6.95 | $3.71 | -47% |
| 2023 | $3.71 | $2.16 | -42% |
| 2024 | $2.16 | $1.56 | -28% |
| 2025 | $1.56 | $2.03 | +30% |
| 2026 YTD | $2.03 | $1.94 | -4.4% |
CERS has finished lower in four of the last six years. It's down 4.4% so far in 2026.